Login to Your Account



Other News To Note


Tuesday, June 12, 2012
• Gilead Sciences Inc., of Foster City, Calif., said the FDA extended the PDUFA date to Sept. 14 for the priority review of Truvada (emtricitabine/tenofovir disoproxil fumarate) to prevent HIV infection in high-risk adults.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription